These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 28058684)

  • 21. A novel strategy for engineering of a smart generation of immune ribonucleases against EGFR
    Taghizadegan N; Firoozrai M; Nassiri M; Ariannejad H
    J Cell Physiol; 2021 Jun; 236(6):4303-4312. PubMed ID: 33421131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Production of a Granulysin-Based, Tn-Targeted Cytolytic Immunotoxin Using Pulsed Electric Field Technology.
    Guerrero-Ochoa P; Aguilar-Machado D; Ibáñez-Pérez R; Macías-León J; Hurtado-Guerrero R; Raso J; Anel A
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32859066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand.
    Guillemard V; Nedev HN; Berezov A; Murali R; Saragovi HU
    DNA Cell Biol; 2005 Jun; 24(6):350-8. PubMed ID: 15941387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.
    Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
    Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and purification of a toxin-linked conjugate targeting epidermal growth factor receptor in Escherichia coli.
    Ma C; Li Y; Li Z; Huang H; Xu K; Xu H; Bai J; Li X; Zhao G
    Protein Expr Purif; 2012 May; 83(1):1-7. PubMed ID: 22381467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability.
    Bera TK; Pastan I
    Bioconjug Chem; 1998; 9(6):736-43. PubMed ID: 9815167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Construction, expression, and characterization of a recombinant immunotoxin targeting EpCAM.
    Lv M; Qiu F; Li T; Sun Y; Zhang C; Zhu P; Qi X; Wan J; Yang K; Zhang K
    Mediators Inflamm; 2015; 2015():460264. PubMed ID: 25960617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An efficient scheme for purification of a novel recombinant immunotoxin, rCCK8PE38, for anti-tumour experiments.
    Hu P; Zhang S; Lu SY; Li M; Chang J; Wang MY; Li C; Zhao K; Guan YT; Zhang YY; Li YS; Zhou Y; Liu ZS; Bai O; Ren HL
    Biomed Chromatogr; 2018 Jun; 32(6):e4197. PubMed ID: 29359465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficient ablation by immunotoxin-mediated cell targeting of the cell types that express human interleukin-2 receptor depending on the internal ribosome entry site.
    Kobayashi T; Kida Y; Kaneko T; Pastan I; Kobayashi K
    J Gene Med; 2001; 3(5):505-10. PubMed ID: 11601764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Construction and expression of novel immunotoxin cpIL-4(13D)-PE38KDEL with increased activity.
    Cui JX; Ji JF; Lv AG; Wu WF
    Biochemistry (Mosc); 2005 Jan; 70(1):62-8. PubMed ID: 15701050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts.
    Mazor Y; Noy R; Wels WS; Benhar I
    Cancer Lett; 2007 Nov; 257(1):124-35. PubMed ID: 17698286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multifunctional Complexes Based on Photoluminescent Upconversion Nanoparticles for Theranostics of the HER2-Positive Tumors.
    Guryev EL; Smyshlyaeva AS; Shilyagina NY; Shanwar S; Kostyuk AB; Shulga AA; Konovalova EV; Zvyagin AV; Deyev SM; Petrov RV
    Dokl Biochem Biophys; 2020 Mar; 491(1):73-76. PubMed ID: 32483755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis of an Anti-CD7 Recombinant Immunotoxin Based on PE24 in CHO and
    Krebs SK; Stech M; Jorde F; Rakotoarinoro N; Ramm F; Marinoff S; Bahrke S; Danielczyk A; Wüstenhagen DA; Kubick S
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
    Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Passive and active targeting of quantum dots for whole-body fluorescence imaging of breast cancer xenografts.
    Balalaeva IV; Zdobnova TA; Krutova IV; Brilkina AA; Lebedenko EN; Deyev SM
    J Biophotonics; 2012 Nov; 5(11-12):860-7. PubMed ID: 22887708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells.
    Schiffer S; Letzian S; Jost E; Mladenov R; Hristodorov D; Huhn M; Fischer R; Barth S; Thepen T
    Cancer Lett; 2013 Dec; 341(2):178-85. PubMed ID: 23973499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Constitutive expression and anticancer potency of a novel immunotoxin onconase-DV3.
    Sun M; Tang H; Gao Y; Dai X; Yuan Y; Zhang C; Sun D
    Oncol Rep; 2016 Apr; 35(4):1987-94. PubMed ID: 26782924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
    Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin.
    Shinohara H; Morita S; Kawai M; Miyamoto A; Sonoda T; Pastan I; Tanigawa N
    J Surg Res; 2002 Feb; 102(2):169-77. PubMed ID: 11796015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
    Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
    Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.